InterWest Venture Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

InterWest Venture Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,700	Closed	-$4.22M	–	7
2022 Q3	$4.22M	Hold	18,700	–	–	13.02%	2
2022 Q2	$3.53M	Hold	18,700	–	–	6.57%	5
2022 Q1	$4.66M	Sell	18,700 -6,797	-27%	-$1.07M	1.78%	6
2021 Q4	$3.97M	Hold	25,497	–	–	2.35%	6
2021 Q3	$5.11M	Hold	25,497	–	–	2.12%	6
2021 Q2	$6.52M	Hold	25,497	–	–	2.06%	5
2021 Q1	$6.77M	Hold	25,497	–	–	1.78%	6
2020 Q4	$9.4M	Hold	25,497	–	–	1.17%	6
2020 Q3	$6.23M	Hold	25,497	–	–	1.8%	5
2020 Q2	$7.34M	Hold	25,497	–	–	6.09%	4
2020 Q1	$5.2M	Hold	25,497	–	–	5.49%	4
2019 Q4	$11.4M	Hold	25,497	–	–	4.91%	4
2019 Q3	$7.84M	Hold	25,497	–	–	3.01%	5
2019 Q2	$8.11M	Sell	25,497 -113	-0.4%	-$39.1K	2.62%	6
2019 Q1	$10.7M	Sell	25,610 -15,786	-38%	-$6.34M	9.87%	5
2018 Q4	$12.6M	Sell	41,396 -11,924	-22%	-$3.85M	17.72%	3
2018 Q3	$19.2M	Hold	53,320	–	–	9.37%	4
2018 Q2	$19.5M	Hold	53,320	–	–	8.24%	5
2018 Q1	$15.8M	Hold	53,320	–	–	6.64%	5
2017 Q4	$22.3M	Hold	53,320	–	–	7.63%	3
2017 Q3	$17.6M	Hold	53,320	–	–	4.58%	5
2017 Q2	$12.6M	Hold	53,320	–	–	2.99%	5
2017 Q1	$18.3M	Hold	53,320	–	–	3.89%	5
2016 Q4	$18.6M	Buy	+53,320	New	+$19.5M	4.44%	5

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

InterWest Venture Management's EIGR Position: Q4 2022 in Review

InterWest Venture Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 18,700 shares — an estimated $4.22M sold.

InterWest Venture Management first reported a position in EIGR in Q4 2016 and held it in 24 quarters. The position peaked at $22.3M in Q4 2017. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

InterWest Venture Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
InterWest Venture Management sold 18,700 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $4.22M.
InterWest Venture Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2016 and held it in 24 quarters.
InterWest Venture Management's Eiger BioPharmaceuticals, Inc. position peaked at $22.3M in Q4 2017.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on InterWest Venture Management's 13F filing for Q4 2022, filed 31 Jan 2023.